Related Experiment Videos
Reversibility of left ventricular hypertrophy
1Royal Brompton and National Heart-Chest Hospital, London, UK.
Insights
Antihypertensive therapies can reverse left ventricular hypertrophy (LVH), a risk factor for heart disease. Combination therapy, ACE inhibitors, and methyldopa were most effective, while vasodilators showed no effect on LVH.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Left ventricular hypertrophy (LVH) is a significant independent risk factor for coronary artery disease.
- Effective antihypertensive strategies are crucial for mitigating cardiovascular complications associated with LVH.
Purpose of the Study:
- To evaluate the efficacy of different antihypertensive therapies in reversing left ventricular hypertrophy (LVH).
- To compare the effects of various drug classes on LVH regression using echocardiographic assessments.
Main Methods:
- Systematic review and meta-analysis of 104 studies.
- Echocardiography used to assess left ventricular mass and wall thickness.
- Comparison of antihypertensive drug classes including ACE inhibitors, vasodilators, beta-blockers, and combination therapies.
Main Results:
- Combination therapy, angiotensin-converting enzyme (ACE) inhibitors, and methyldopa demonstrated the most significant LVH reversal.
- Vasodilators (minoxidil, hydralazine) showed no effect on LVH.
- Beta-blockers were comparable to ACE inhibitors in reducing LV wall thickness, independent of blood pressure reduction or therapy duration.
Conclusions:
- Specific antihypertensive drug classes exhibit differential effects on LVH regression.
- Reversal of LVH through antihypertensive therapy may be linked to reduced cardiovascular events.
- Further research into the mechanisms underlying these drug-specific effects is warranted.
Abstract:
Left ventricular hypertrophy (LVH) is a powerful independent risk factor for coronary artery disease. This overview of 104 studies examines the ability of various types of antihypertensive therapies to reverse LVH as assessed by echocardiography. Combination therapy, angiotensin converting enzyme (ACE) inhibitors, and methyldopa were the most effective in reversing LV mass; vasodilators such as minoxidil and hydralazine had no effect on LVH. These differences were independent of the degree of fall in blood pressure and duration of therapy. beta-blockers were as effective as ACE inhibitors in decreasing LV wall thickness. Possible reasons for drug differences in reversing LVH are discussed. Preliminary evidence suggests that reversing LVH by antihypertensive drug therapy is associated with a reduction in cardiovascular complications.